cystic-fibrosis

Documents about cystic-fibrosis

• Exercise Capacity, Muscle Oxygenation, Respiratory Muscle Strength, and Physical Activity Level in Pediatric CF and PCD#860158ClinicalTrials.gov
• A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele#914128ClinicalTrials.gov
• Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex#628558ClinicalTrials.gov
• Cystic fibrosis carrier screening in Veneto (Italy): an ethical analysis#703581PhilArchive
• Feasibility of Cough Monitoring in Children#854185ClinicalTrials.gov
• Exercise Training in Patients With Non-cystic Fibrosis (CF) Bronchiectasis#908110ClinicalTrials.gov
• Pharmacokinetics of FDL169 in Healthy Female Subjects#1046075ClinicalTrials.gov
• Obstetric and neonatal outcomes in pregnancies from a dedicated cystic fibrosis-maternal health service: a retrospective study#393587Spiral
• Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function#894992ClinicalTrials.gov
• Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials#904202ClinicalTrials.gov
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation#980560ClinicalTrials.gov
• Machine Learning Prediction of Pulmonary Function in Children With Cystic Fibrosis#1030420ClinicalTrials.gov
• Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections#146218ClinicalTrials.gov
• Oral Nutritional Supplements in Adults with Cystic Fibrosis: Effects on Intake, Levels of Fat-Soluble Vitamins, and Bone Remodeling Biomarkers#646733Repisalud
• Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis#834835ClinicalTrials.gov
• Cystic Fibrosis Mortality Trends 1999-2024-A CDC Wonder Study.#402763NCBI PubMed Central
• Energy Balance and Weight Gain With Ivacaftor Treatment#810777ClinicalTrials.gov
• RHEology of the Pulmonary MUcus#812722ClinicalTrials.gov
• Assessment of Inflammatory Mediators (AIM)#884616ClinicalTrials.gov
• CFTR Related Pancreatitis Study#908841ClinicalTrials.gov
• A Study to Investigate Lung Deposition of Radiolabelled OligoG#918909ClinicalTrials.gov
• Feasibility of a Mobile Medication Plan Application in CF Patient Care#878601ClinicalTrials.gov
• A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis#862169ClinicalTrials.gov
• Effects of Inspiratory Muscle Training on Postural Stability, Balance, Pulmonary Function and Functional Capacity in Children With Cystic Fibrosis#871913ClinicalTrials.gov
• Use of Calgary and microfluidic BioFlux systems to test the activity of fosfomycin and tobramycin alone and in combination against cystic fibrosis Pseudomonas aeruginosa biofilms#955227Koc University Digital Collections
• Data Management and Sharing Plan for: UNC Cystic Fibrosis Research and Translation Core Center#297942UNC Dataverse Dataverse OAI Archive
• STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)#300290ClinicalTrials.gov
• A Study of the Clinical Benefit of Tobramycin Inhalation Solution#683102ClinicalTrials.gov
• WGS of Korean Idiopathic Bronchiectasis#908734ClinicalTrials.gov
• Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI#994986ClinicalTrials.gov
• The Relationship Between CFTR Gene Mutations and Exercise Capacity#1032045ClinicalTrials.gov
• In host evolution of Exophiala dermatitidis in cystic fibrosis lung micro-environment#491844eScholarship
• Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del -gating and F508del -residual function genotypes: results from an open-label extension study#971087HAL (France)
• Egresos hospitalarios por fibrosis quística en pacientes de 0 a 19 años en Chile: Estudio descriptivo, 2021-2024#236970Repositorio Universidad del Desarrollo
• Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry#433545IRIS
• The Impact of Cystic Fibrosis‐Related Diabetes on Barriers to Self‐Management.#193382NCBI PubMed Central
• A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy#805582ClinicalTrials.gov
• A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE#839656ClinicalTrials.gov
• Increased Vitamin D Reduces Pulmonary Exacerbations in CF#872273ClinicalTrials.gov
• T Cell Memory Fuels the Innate Response in Chronic CF Lung Disease#875016ClinicalTrials.gov
• Comparison of Antibiotics for Pseudomonas in Early CF#901458ClinicalTrials.gov
• Prospective Analysis of Urine LAM to Eliminate NTM Sputum Screening#903259ClinicalTrials.gov
• Assessment of Rheological Parameters of Human Sputum.#1008299ClinicalTrials.gov
• 3 Airway Clearance Techniques in Non Cystic Fibrosis Bronchiectasis#1030232ClinicalTrials.gov
• Lung Ultrasound in Cystic Fibrosis: A Systematic Review of Clinical Utility, Scoring Systems, and Correlation With Structural and Functional Outcomes#156444HAL (France)
• Supporting the goals and ideals of National Cystic Fibrosis Awareness Month.#128870Congress.gov
• "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"#141061ClinicalTrials.gov
• A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies#152452ClinicalTrials.gov
• Natural History of Bronchiectasis#201812ClinicalTrials.gov
• Azithromycin to Modify Bronchiectasis Exacerbation Risk#253035ClinicalTrials.gov